The EuroHeart Failure survey programme - A survey on the quality of care among patients with heart failure in Europe. Part 2: Treatment

European Heart Journal

Volumn 24, Issue 5, 2003, Pages 464-474

  Komajda, M ^b   Follath, F ^c   Swedberg, K ^c   Cleland, J ^c   Aguilar, J C ^c   Cohen Solal, A ^c   Dietz, R ^c   Gavazzi, A ^c   Van Gilst, W H ^c   Hobbs, R ^c   Korewicki, J ^c   Madeira, H C ^c   Moiseyev, V S ^c   Preda, I ^c   Widimsky, J ^c   Freemantle, N ^a   Eastaugh, J ^a   Mason, J ^c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c NONE

Author keywords

Heart failure; Medical treatment; Survey

Indexed keywords

ACETYLSALICYLIC ACID; AMILORIDE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUMETANIDE; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARDIAC GLYCOSIDE; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOPAMINE; ENALAPRIL; FUROSEMIDE; INOTROPIC AGENT; LISINOPRIL; METOLAZONE; METOPROLOL; NITRATE; PERINDOPRIL; RAMIPRIL; SOTALOL; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TORASEMIDE; TRIAMTERENE; UNINDEXED DRUG;

ADULT; AGE; AGED; ARTICLE; COMORBIDITY; DIABETES MELLITUS; DIURETIC THERAPY; EUROPE; FEMALE; HEALTH CARE QUALITY; HEALTH SURVEY; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MODEL; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SUPRAVENTRICULAR TACHYCARDIA; WARD;

ADRENERGIC BETA-ANTAGONISTS; AGE FACTORS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPIRIN; CALCIUM CHANNEL BLOCKERS; CARDIAC GLYCOSIDES; CARDIAC OUTPUT, LOW; CARDIOVASCULAR AGENTS; EUROPE; FEMALE; FIBRINOLYTIC AGENTS; HEALTH SURVEYS; HOSPITALIZATION; HUMANS; MALE; MULTIVARIATE ANALYSIS; PLATELET AGGREGATION INHIBITORS; QUALITY OF HEALTH CARE; SPIRONOLACTONE;

EID: 0344806945     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-668X(02)00700-5     Document Type: Article

References (22)

1. Ho K, Pinsky J, Kannel W et al. The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol 1993;22(Suppl A):6A-13A.
2. McMurray J, Hart W, Rhodes G. An evaluation of the cost of heart failure to the National Health Service in the UK. Br J Med Econ 1993;285:99-110.
3. Andrews R, Cowley AJ. Clinical and economic factors in the treatment of congestive heart failure. Pharmacoeconomics 1995;7:119-27.
4. Cohen-Solal A, Desnos M, Delahaye F et al. for the myocardial and heart failure working group of the French Society of Cardiology, the National College of General Hospital Cardiologists and the French Geriatrics Society. A national survey of heart failure in French hospitals. Eur Heart J 2000;21:763-9.
5. Komajda M, Bouhour JB, Amouyel P et al. Ambulatory heart failure management in private practice in France. Eur J Heart Failure 2001;3:503-7.
6. Taubert G, Bergmeier C, Andresen H et al. Clinical profile and management of heart failure: rural community hospital vs metropotitan heart center. Eur J Heart Failure 2001; 3:611-7.
7. Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-60.
8. Collett D. Modelling binary data. London: Chapman and Hall; 1991.
9. Task Force of the Working Group on Heart Failure of the European Society of Cardiology. Guidelines: the treatment of heart failure. Eur Heart J 1997;18:736-53.
10. Zannad F, Briancon S, Juilliere Y et al. and the EPICAL Investigators. Incidence, clinical and etiologic features and outcomes of advanced Chronic Heart Failure: the EPICAL Study. J Am Coll Cardiol 1999;33:734-42.
11. Cleland JGF, Cohen-Solal A, Cosin-Aguilar J, et al. An International Survey of the management of heart failure in primary care. The IMPROVEMENT of Heart Failure Programme. Lancet [in press].
12. Krum H, Tonkin AM, Currie J et al. Chronic heart failure in Australian general practice. The cardiac Awareness Survey and Evaluation (CASE) Study. Med J Aust 2001;174:439-44.
13. McMurray JJV. Failure to practice evidence-based medicine: why do physicians not treat patients with heart failure with angiotensin-converting enzyme inhibitors? Eur Heart J 1998; 19(Suppl L):L15-21.
14. Hougthon AR, Cowley AJ. Why are angiotensin converting enzyme inhibitors under-utilized in the treatment of heart failure by general practitioners? Int J Cardiol 1997;59:7-10.
15. Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. PROGRESS Collaborative Group. Lancet 2001;358:1033-41.
16. Banerjee P, Banerjee T, Khand A et al. Diastolic heart failure: neglected or misdiagnosed? J Am Coll Cardiol 2002; 39:138-41.
17. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
18. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.
19. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker Valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
20. Digitalis Intervention Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.
21. ATLAS Study Group. Comparative effects of low and high doses of the angiotensin-converting-enzyme inhibitor, lisinoprit, on morbidity and mortality in chronic heart failure. Circulation 1999;100:2312-8.
22. Sturm B, Pacher R, Strametz-Juranek J et al. Effect of beta-1 blockade with atenolol on progression of heart failure in patients pretreated with high-dose enalapril. Eur J Heart Failure 2000;2:407-12.